PCN162 A COST MINIMISATION ANALYSIS OF 24-MONTH FIXED DURATION OF VENETOCLAX PLUS RITUXIMAB VERSUS IBRUTINIB FOR RELAPSED AND REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA IN PORTUGAL
| Autor: | Silva Miguel, L., Paquete, A.T., Pereira, J.M., Ramos, I., Alarcão, J., Borges, M. |
|---|---|
| Zdroj: | In Value in Health November 2019 22 Supplement 3:S467-S467 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|
Full Text from ScienceDirect